Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by equities research analysts at Piper Jaffray Companies in a report issued on Friday, November 17th. They currently have a $182.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 46.10% from the company’s previous close.
ALNY has been the topic of several other research reports. Credit Suisse Group increased their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Needham & Company LLC reissued a “buy” rating and set a $85.00 price target (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price target for the company. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, September 11th. Finally, Nomura initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 14th. They set a “reduce” rating and a $56.00 price target for the company. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average target price of $121.85.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down $2.43 during mid-day trading on Friday, hitting $124.57. 974,249 shares of the company were exchanged, compared to its average volume of 1,148,462. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a 12 month low of $35.98 and a 12 month high of $147.63.
In related news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the sale, the senior vice president now directly owns 41,500 shares in the company, valued at $5,639,435. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The disclosure for this sale can be found here. Insiders sold 393,212 shares of company stock valued at $48,109,436 over the last quarter. Company insiders own 4.30% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Prudential Financial Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $215,000. Teachers Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 9.1% during the first quarter. Teachers Advisors LLC now owns 80,238 shares of the biopharmaceutical company’s stock valued at $4,112,000 after purchasing an additional 6,662 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Alnylam Pharmaceuticals by 1.3% during the first quarter. Dimensional Fund Advisors LP now owns 112,778 shares of the biopharmaceutical company’s stock valued at $5,780,000 after purchasing an additional 1,428 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $2,619,000. Finally, Capstone Asset Management Co. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $232,000. Institutional investors own 88.43% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Alnylam Pharmaceuticals (ALNY) Given Buy Rating at Piper Jaffray Companies” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2017/12/06/alnylam-pharmaceuticals-inc-alny-given-buy-rating-at-piper-jaffray-companies.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.